Assessing immune profiles to predict responses to cancer immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the predictive value of immune-methylation profiling in patients undergoing FDA-approved immunotherapy for various types of cancer. It will analyze both pre-treatment and on-treatment immune-methylation and cytokine profiles to determine their effectiveness in predicting treatment responses. The study focuses on patients receiving therapies such as checkpoint inhibitors and cellular immunotherapy, regardless of their prior treatment history.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals

Where it's running

• Dartmouth-Hitchcock Medical Center
  Lebanon, New Hampshire, United States Recruiting

Study contacts

• Principal investigator: Brock C Christensen, PhD — Dartmouth College
• Study coordinator: Brock C Christensen, PhD
• Email: brock.c.christensen@dartmouth.edu
• Phone: 603-650-1827

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improving quality of life for blood cancer patients receiving cellular therapy

  This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05646576

• Improving leukemia diagnosis using artificial intelligence

  This study is testing whether an artificial intelligence system can improve the diagnosis of leukemia by comparing its accuracy and speed to traditional methods using a large set of blood samples.

  Recruiting Munich Leukemia Laboratory · Munich, Bavaria · NCT04466059

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.